London, UK – 05 November 2025: British biotechnology company Cizzle Biotechnology Holdings plc (LSE: CIZ) has taken a major step toward transforming lung cancer diagnosis in the UK. The company has signed a Letter of Intent (LOI) with a leading UK-based clinical laboratory provider to introduce its CIZ1B blood test, a simple and highly accurate tool for the early detection of lung cancer, to the National Health Service (NHS).

This intended partnership represents a breakthrough in cancer diagnostics, aiming to make Cizzle’s pioneering test, already licensed in North America, widely accessible across NHS and private healthcare networks in the UK. The CIZ1B biomarker test is non-invasive, affordable, and capable of identifying lung cancer in its earliest stages, often before symptoms appear and when treatment outcomes are significantly better.

Under the terms of the LOI, the laboratory partner will conduct verification and validation of the test in collaboration with one of its NHS Foundation Trust partners. If successful, this could lead to a formal agreement designating the laboratory as Cizzle Biotech’s exclusive UK provider, supporting a co-branded rollout throughout the country’s healthcare system.

Lung cancer continues to be one of the most lethal cancers in the UK, claiming around 35,000 lives each year, which accounts for roughly one in five cancer-related deaths. Globally, cancer remains a leading cause of death, responsible for nearly 10 million fatalities annually.

Early diagnosis is the key to improving survival rates, aligning with the NHS Long Term Plan, which targets diagnosing 75% of cancers at stages 1 or 2 by 2028, a milestone that could save up to 55,000 lives every year. Innovations like Cizzle’s CIZ1B test could be instrumental in reaching that target by detecting cancer at its most treatable point.

The CIZ1B biomarker blood test is the result of over ten years of dedicated research led by Professor Dawn Coverley, Founder and Chief Scientific Officer of Cizzle Biotech, at the University of York, with the support of Yorkshire Cancer Research. Designed to be a quick and non-invasive alternative to imaging-based diagnostics such as CT scans or biopsies, the test simplifies early lung cancer screening and promises to reduce the burden on radiology departments across the NHS.

If the partnership proceeds as expected, Cizzle Biotech’s innovation could mark a turning point in cancer diagnostics, giving clinicians and patients a faster, safer, and more effective way to identify lung cancer early, when it matters most.

In a report by pharmiweb, Allan Syms, Executive Chairman of Cizzle Biotechnology said: From Research Lab to Real-World Impact   “Our work has been focused on the goal of making early cancer detection accessible at scale,” “This LOI is a major milestone for Cizzle, and for the future of early cancer detection in the UK.”   “This is about getting ahead of cancer, not chasing it when the cancer has already become well advanced. The ability to detect lung cancer early, through a simple, non-invasive test, has the potential to save thousands of lives every year and ease pressure on the NHS.   “We’re also deeply grateful to our shareholders for their continued support. Their confidence allows us to take innovation out of the lab and into hospitals where it can make a real difference to patients and their families.” 

The LOI builds on Cizzle Biotech’s growing international traction. The company previously signed a US$2.4 million licensing deal for North America and the Caribbean, with US$530,000 already received. In the U.S., Cizzle supports its partner Cizzle Bio Inc. as it advances CLIA accreditation and clinical studies with the Moffitt Cancer Center in Florida.

To accelerate commercial rollout, Cizzle raised an additional £250,000 in convertible loan notes from long-term shareholder Frazer Lang, following a £150,000 note issued in May 2025. The funding will support test validation with its UK lab partner and expand UK and European operations.

With this agreement, Cizzle Biotech moves closer to redefining early cancer detection in the UK, turning cutting-edge science into lifesaving, accessible healthcare solutions.